Ahmedabad, India
Intas Pharmaceuticals, founded in 2000, stands as a leading multinational organization in the pharmaceutical formulation sector, with a progressive 19% CAGR and impressive revenues surpassing the $2.5 billion mark. The company's extensive global reach spans over 85+ countries, with 70% of revenue generated internationally.
As the largest privately owned generic pharma company in India, Intas holds a significant presence in the healthcare industry. Its pivotal markets include the EU, US, and UK, where Intas ranks among the top ten generic players. It operates 17 cutting-edge formulation and R&D facilities, essential for its robust pipeline of 300+ high-value products, catering to therapeutic segments like Oncology and Diabeto, underlining its mission of providing “Biosimilars for Billions.”
The company's remarkable journey is supported by substantial investments in R&D, approximately 6-7% of its revenues, ensuring a diverse and strategic growth trajectory. Intas recently secured a $235.61M secondary market investment from the Abu Dhabi Investment Authority, indicating strong investor confidence in its strategic vision.
